Early prostate-specific antigen response post-abiraterone as predictor of overall survival in metastatic castrate-resistant prostate cancer

BACKGROUND: Abiraterone is an important agent in the treatment of advanced prostate cancer. Early changes in prostate-specific antigen while on abiraterone in patients with metastatic castrate-resistant prostate cancer potentially have financial and health implications for patients. Limited data is...

Descripción completa

Detalles Bibliográficos
Autores principales: Schiff, Joshua P., Cotogno, Patrick, Feibus, Allison, Steinwald, Peter, Ledet, Elisa, Lewis, Brian, Sartor, Oliver
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6544996/
https://www.ncbi.nlm.nih.gov/pubmed/31151428
http://dx.doi.org/10.1186/s12885-019-5729-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6544996/
https://www.ncbi.nlm.nih.gov/pubmed/31151428
http://dx.doi.org/10.1186/s12885-019-5729-7

Ejemplares similares